Colleen Craig

VP, Metabolic Diseases at Eiger BioPharmaceuticals

Dr. Colleen Craig joined Eiger in 2015 and serves as the Vice President, Metabolic Diseases overseeing the avexitide development program.

Dr. Craig worked in the Division of Endocrinology at Stanford University School of Medicine, where her research centered on incretin hormones and their role in in hyperinsulinemic hypoglycemic conditions, including post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism (HI). Dr. Craig was the recipient of several prestigious awards including the National Institute of Health’s Career Development Award, Stanford’s SPARK Award and Stanford’s Translational and Applied Medicine (TRAM) Research Award. She has led clinical investigations establishing the critical role of the incretin gut hormone glucagon-like peptide-1 (GLP-1) in mediating PBH and other forms of hyperinsulinemic hypoglycemia. She has also authored numerous publications and holds several patents that support Eiger’s development of avexitide for the treatment of PBH and HI.

Dr. Craig obtained her M.D. from Brown University School of Medicine and completed her postdoctoral research fellowship at Stanford University School of Medicine.

Links

Timeline

  • VP, Metabolic Diseases

    May, 2021 - present

View in org chart